- Posted by ISPE Boston
- On May 21, 2020
WuXi Biologics and the Worcester Business Development Corporation (WBDC) have announced the successful signing of a land deal for WuXi Biologics’ clinical and commercial manufacturing facility (MFG11) in Worcester at The Reactory, a 46-acre master-planned biomanufacturing campus. The approximately 107,000-square-foot, two-story facility will be operational in 2022 and create 150 new jobs.
Craig Blais, the president and CEO of the WBDC, stated, “WuXi Biologics’ decision to locate its first US biomanufacturing facility in Worcester at The Reactory confirms the value of Worcester’s strong life sciences ecosystem. We expect other biotech manufacturers will soon follow their lead.”
“We are proud to join the Worcester community and greater region as a tenant of The Reactory, and I thank the city of Worcester for its collaboration,” said Dr. Chris Chen, CEO of WuXi Biologics. “Drawing from the talented workforce and impressive biotech network in Massachusetts, we stand ready and able to help our global partners advance their innovative and life-saving ideas. Together, I am confident that we have much to contribute to the biologics industry and patients worldwide.”
As described on its website, WuXi Biologics is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. As of December 31, 2019, WuXi had a total of 250 integrated projects underway, including 121 projects in pre-clinical development stage, 112 projects in early-phase (phase I and II) clinical development, 16 projects in late-phase (phase III) development and one project in commercial manufacturing. WuXi’s total capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany and Singapore is estimated to exceed 280,000 liters by 2022. (Source: WuXi Biologics Website, 05.19.20)